What is ELVN's market cap?

$3.46B, based on the Nov 4 close of $47.25.

Does Enliven Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ELVN is sold short?

9.3M shares, 16.4% of float, as of Oct 15, 2026.

What sector is ELVN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ELVNHealthcarePharmaceuticals

Enliven Therapeutics, Inc. Common Stock (ELVN)

$47.25+5.40%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$47.25▲ 148.55% in range

Nov 4, 2025Low $15.14 · High $61.15Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Enliven Therapeutics closed at $47.25 on Nov 4, up 5.40%, 22.7% below its 52-week closing high. Volume of 2.7M shares was 1.68× its 20-day average (above normal).

Split-adjusted performance: +11.5% over one month, +14.7% over six months, +136.2% over one year.

Short interest was 9.3M shares at the Oct 15 settlement, down 9.9% from the prior report (16.4% of float, 7.5 days to cover).

Market cap$3.46B73.3M shares

Revenue · quarter$0.00—

Diluted EPS$-0.49—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range15.14 – 61.15−22.7% from high

Volume2.7M1.68× 20-day avg

Volatility · 60d41.7%Annualised

Short % of float16.4%7.5 days to cover

Net cash$895.2MCash $895.2M

Next earnings—Not scheduled

Split-adjusted performance

1W +5.5%1M +11.5%3M −21.6%6M +14.7%YTD +206.8%1Y +136.3%3Y +294.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum79

Revenue growth—

Net margin—

Value (low P/E)—

Size86

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short9.3M−9.9% vs prior

Days to cover7.5Settled Oct 15

% of float16.4%

Short vol. 10d67.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ELVNEnliven Therapeutics	$47.25	+5.40%	+14.7%	—	—	—	$3.46B
DYNDyne Therapeutics	$18.54	+2.71%	−1.6%	—	—	—	$3.46B	Compare
VKTXViking Therapeutics	$27.97	+7.21%	−13.4%	—	—	—	$3.57B	Compare
OGNOrganon &	$13.83	−0.14%	+3.1%	−1.7%	10.4%	17.1	$3.63B	Compare
VRDNViridian Therapeutics	$29.06	+15.53%	+65.7%	+278.7%	−39726.8%	—	$3.29B	Compare
AMLXAmylyx Pharmaceuticals	$29.40	+0.68%	+83.1%	—	—	—	$3.69B	Compare
IRONDisc Medicine	$83.28	+2.61%	+21.3%	—	—	—	$3.70B	Compare
ACADAcadia Pharmaceuticals	$21.47	+4.38%	0.0%	+16.4%	10.2%	9.7	$3.70B	Compare
PBLSParabilis Medicines	$30.36	+3.79%	—	—	−45239.9%	—	$3.75B	Compare

News about Enliven Therapeutics

All news →

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyThe Motley Fool · Jun 27, 2026Neutral Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?The Motley Fool · Jun 24, 2026Neutral Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.The Motley Fool · Jun 1, 2026Neutral

Quick answers

What does Enliven Therapeutics do?: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
What is ELVN's market cap?: $3.46B, based on the Nov 4 close of $47.25.
Does Enliven Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ELVN is sold short?: 9.3M shares, 16.4% of float, as of Oct 15, 2026.
What sector is ELVN in?: Healthcare, in the Pharmaceuticals industry.

About Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

HQ: Burlingame, CA67 employeesListed Feb 24, 2023enliventherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology